New York (February 27th, 2013) - Radian Group Inc. (NYSE:RDN) announced that it has commenced two separate underwritten public offerings of up to 30 million shares of its common stock and $200 million aggregate principal amount of its convertible senior notes due 2019. The convertible senior notes will be convertible into shares of the Company’s common stock, cash or a combination of shares of common stock and cash, at the Company’s election.
Morgan Stanley & Co. LLC and Goldman, Sachs & Co. will act as joint book-running managers for the Offerings.
The Company intends to use the net proceeds from the Offerings to fund working capital requirements and for general corporate purposes, including additional capital support for our mortgage insurance business.
Get the latest trend analysis reports for RDN here: http://www.wallstreetreport.net/market-scan/?symbol=RDN
Celldex Therapeutics, Inc. (NASDAQ:CLDX) deep product pipeline consists of products in varying stages of development, with lead candidates CDX-110 preparing to enter a Phase 3 clinical trial in newly diagnosed glioblastoma multiforme, one of the most aggressive forms of brain cancer, and CDX-011 currently undergoing evaluation in a Phase 2b clinical trial in advanced breast cancer.
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company markets Rotarix to treat rotavirus infection. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.
Get the latest trend analysis reports for CLDX here: http://www.wallstreetreport.net/market-scan/?symbol=CLDX
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetReport.net
Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit: www.wallstreetreport.net/disclaimer-2/
WALL STREET REPORT[email protected]